Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Sunday, April 9, 2017

Ocrevus (Ocrelizumab) Information Update

Click here to receive MS news via e-mail

Ocrevus - what is it?

What is it? Ocrelizumab is an antibody based medication that depletes the B cells in patients' circulation (largely in the blood). It is given via an infusion (intravenously) every 6 months. It was developed based on the promising results from trials of another B cell depleting medication called rituximab. The therapeutic benefits in relapsing remitting MS and in primary progressive MS were recently reported.

What are the steps involved in accessing this treatment? If you are interested in learning more about this medication, please schedule a follow-up with your neurologist to discuss Ocrevus in more detail and see if it is the right fit for you. If you and your neurologist decide to move forward with Ocrevus, our office will work with your insurance to see if it is covered. If the medication is covered and screening tests reveal no contraindications, our office will help you schedule the infusion at UCSF or at an alternate infusion center.

information source: found here

MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

No comments: